The New Paradigm
Ultro-Minimum Incision Personalized Intratumoral Chemoimmunotherapy (UMPIC) creates a new blue ocean in cancer treatment.
This project revolutionarily extends the application of immunotherapy from late-stage systemic treatment to the early perioperative period of tumors. Our proposed "Cancer Immune Surgery" paradigm aims to pre-treat the tumor before surgical resection, physically remove the lesion while initiating long-term immune memory during the operation.
By doing so, we clean up micrometastases at the source and significantly reduce the risk of postoperative recurrence, solving the century-old dilemma of traditional surgery: "removing but not preventing".
Key Achievements: Over 100,000 cases treated, 92.63% clinical benefit rate, and orphan drug designation by the US FDA.
